Trial · NCT03258554
Results by group29
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 29
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Dose-limiting Toxicity (DLT) [Lead-in Phase] | (Lead-in) RT + Durvalumab | 0 | Participants | ||
| Progression-free Survival (Percentage of Participants Alive Without Progression) [Phase II Primary] | RT + Cetuximab | 63.7 | 95% Confidence Interval 51.3 to 76.1 | percentage of participants | |
| Progression-free Survival (Percentage of Participants Alive Without Progression) [Phase II Primary] | RT + Durvalumab | 50.6 | 95% Confidence Interval 41.5 to 59.8 | percentage of participants | |
| Overall Survival (Percentage of Participants Alive) [Originally Phase III Primary / Now Phase II Secondary] | RT+ Cetuximab | 77.5 | 95% Confidence Interval 66.7 to 88.3 | percentage of participants | |
| Overall Survival (Percentage of Participants Alive) [Originally Phase III Primary / Now Phase II Secondary] | RT + Durvalumab | 69.3 | 95% Confidence Interval 60.8 to 77.8 | percentage of participants | |
| Locoregional Failure (Percentage of Participants With Locoregional Failure) | RT+ Cetuximab | 18.9 | 95% Confidence Interval 10.0 to 29.9 | percentage of participants | |
| Locoregional Failure (Percentage of Participants With Locoregional Failure) | RT + Durvalumab | 31.3 | 95% Confidence Interval 23.0 to 40.0 | percentage of participants | |
| Distant Metastasis (Percentage of Participants With Distant Metastasis) | RT+ Cetuximab | 12.1 | 95% Confidence Interval 5.3 to 22.0 | percentage of participants | |
| Distant Metastasis (Percentage of Participants With Distant Metastasis) | RT + Durvalumab | 9.5 | 95% Confidence Interval 5.0 to 15.7 | percentage of participants | |
| Competing Mortality (Percentage of Participants Who Died Due to Causes Other Than Study Cancer) | RT+ Cetuximab | 5.3 | 95% Confidence Interval 1.4 to 13.4 | percentage of participants | |
| Competing Mortality (Percentage of Participants Who Died Due to Causes Other Than Study Cancer) | RT + Durvalumab | 10.5 | 95% Confidence Interval 5.7 to 17.0 | percentage of participants | |
| Percentage of Participants With Complete or Partial Response at 4-month Scan Determined by Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1 | RT+ Cetuximab | 72.7 | 95% Confidence Interval 51.8 to 86.8 | percentage of participants | |
| Percentage of Participants With Complete or Partial Response at 4-month Scan Determined by Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1 | RT + Durvalumab | 75.9 | 95% Confidence Interval 57.9 to 87.8 | percentage of participants | |
| Number of Participants by Highest Grade Adverse Event Reported | RT+ Cetuximab | < Grade 3 | 12 | Participants | |
| Number of Participants by Highest Grade Adverse Event Reported | RT + Durvalumab | < Grade 3 | 36 | Participants | |
| Number of Participants by Highest Grade Adverse Event Reported | RT+ Cetuximab | Grade 3 | 37 | Participants | |
| Number of Participants by Highest Grade Adverse Event Reported | RT + Durvalumab | Grade 3 | 57 | Participants | |
| Number of Participants by Highest Grade Adverse Event Reported | RT+ Cetuximab | Grade 4 | 11 | Participants | |
| Number of Participants by Highest Grade Adverse Event Reported | RT + Durvalumab | Grade 4 | 15 | Participants | |
| Number of Participants by Highest Grade Adverse Event Reported | RT+ Cetuximab | Grade 5 | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03258554/results